Keyword: Germany

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

Esteve has a deal to buy a specialty drug manufacturing plant in Germany after selling a its generics business and plant in Spain.

AGC Biologics has completed manufacturing improvements at its site in Heidelberg, Germany. With it comes the expansion of its plasmid DNA capacity.

Boehringer Ingelheim has recruited label design and management specialist NiceLabel to develop a global standardized labeling process.

Merz has made two separate investments in its Dessau sites, one for its branded cosmetic drug production and one for its CDMO operations.

IDT Biologika has a new human vaccine manufacturing facility as its narrows its focus to the development and production of human vaccines only.

Germany’s health technology assessment agency found that the majority of new drugs provide little or no added benefit over standard care.

Boehringer Ingelheim has invested €225 million on inhaler production with a new plant in Spain and expanded lines in Germany.